Innovative approaches to anti-arrhythmic drug therapy

被引:150
作者
Nattel, Stanley
Carlsson, Leif
机构
[1] Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada
[2] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada
[3] AstraZeneca Res & Dev, Integrat Pharmacol, S-43183 Molndal, Sweden
基金
加拿大健康研究院;
关键词
D O I
10.1038/nrd2112
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Normal cardiac function requires an appropriate and regular beating rate (cardiac rhythm). When the heart rhythm is too fast or too slow, cardiac function can be impaired, with derangements that vary from mild symptoms to life-threatening complications. Irregularities, particularly those involving excessively fast or slow rates, constitute cardiac 'arrhythmias'. In the past, drug treatment of cardiac arrhythmias has proven difficult, both because of inadequate effectiveness and a risk of serious complications. However, a variety of recent advances have opened up exciting possibilities for the development of novel and superior approaches to arrhythmia therapy. This article will review recent progress and future prospects for treating two particularly important cardiac arrhythmias: atrial fibrillation and ventricular fibrillation.
引用
收藏
页码:1034 / 1049
页数:16
相关论文
共 168 条
[61]  
Gross GJ, 2000, BASIC RES CARDIOL, V95, P280, DOI 10.1007/s003950050004
[62]   Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration [J].
Grover, R ;
Dhein, S .
PEPTIDES, 2001, 22 (07) :1011-1021
[63]   Is there a future for antiarrhythmic drug therapy? [J].
Guerra, PG ;
Talajic, M ;
Roy, D ;
Dubuc, M ;
Thibault, B ;
Nattel, S .
DRUGS, 1998, 56 (05) :767-781
[64]   Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43 [J].
Gutstein, DE ;
Morley, GE ;
Tamaddon, H ;
Vaidya, D ;
Schneider, MD ;
Chen, J ;
Chien, KR ;
Stuhlmann, H ;
Fishman, GI .
CIRCULATION RESEARCH, 2001, 88 (03) :333-339
[65]   Oral delivery of peptide drugs -: Barriers and developments [J].
Hamman, JH ;
Enslin, GM ;
Kotzé, AF .
BIODRUGS, 2005, 19 (03) :165-177
[66]   Properties of potassium currents in Purkinje cells of failing human hearts [J].
Han, W ;
Zhang, LM ;
Schram, G ;
Nattel, S .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 283 (06) :H2495-H2503
[67]   Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells [J].
Han, W ;
Wang, ZG ;
Nattel, S .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 280 (03) :H1075-H1080
[68]  
Hashimoto N, 2005, CIRCULATION, V112, pU247
[69]   The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress [J].
Haugan, K ;
Olsen, KB ;
Hartvig, L ;
Petersen, JS ;
Holstein-Rathlou, NH ;
Hennan, JK ;
Nielsen, MS .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2005, 16 (05) :537-545
[70]   Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers - A meta-analysis [J].
Healey, JS ;
Baranchuk, A ;
Crystal, E ;
Morillo, CA ;
Garfinkle, M ;
Yusuf, S ;
Connolly, SJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (11) :1832-1839